Debt-to-equity of BioXcel Therapeutics, Inc. from 30 Sep 2018 to 30 Sep 2025

Taxonomy & unit
ratio: %
Description
Debt-to-equity (D/E) ratio is used to evaluate a company's financial leverage and is calculated by dividing a company's total liabilities by its shareholder equity.
Summary
BioXcel Therapeutics, Inc. quarterly Debt-to-equity in % history and change rate from 30 Sep 2018 to 30 Sep 2025.
  • BioXcel Therapeutics, Inc. Debt-to-equity for the quarter ending 30 Sep 2025 was -139%, a 28% increase year-over-year.
Debt-to-equity, Quarterly (%)
Debt-to-equity, YoY Quarterly Change (%)

BioXcel Therapeutics, Inc. Quarterly Debt-to-equity (%)

Period Value YoY Chg Change % Date
Q3 2025 -139% +55% +28% 30 Sep 2025
Q2 2025 -140% +92% +40% 30 Jun 2025
Q1 2025 -156% +187% +55% 31 Mar 2025
Q4 2024 -172% +1220% +88% 31 Dec 2024
Q3 2024 -194% -753% -135% 30 Sep 2024
Q2 2024 -232% -426% -220% 30 Jun 2024
Q1 2024 -342% -451% -415% 31 Mar 2024
Q4 2023 -1393% -1454% -2350% 31 Dec 2023
Q3 2023 559% +526% +1571% 30 Sep 2023
Q2 2023 194% +177% +1087% 30 Jun 2023
Q1 2023 109% +102% +1472% 31 Mar 2023
Q4 2022 62% +55% +837% 31 Dec 2022
Q3 2022 33% +27% +438% 30 Sep 2022
Q2 2022 16% +9.7% +146% 30 Jun 2022
Q1 2022 6.9% -2.3% -25% 31 Mar 2022
Q4 2021 6.6% -4.5% -40% 31 Dec 2021
Q3 2021 6.2% -9.2% -60% 30 Sep 2021
Q2 2021 6.6% -20% -75% 30 Jun 2021
Q1 2021 9.2% -17% -64% 31 Mar 2021
Q4 2020 11% -19% -63% 31 Dec 2020
Q3 2020 15% -8.3% -35% 30 Sep 2020
Q2 2020 26% +9.5% +57% 30 Jun 2020
Q1 2020 26% +16% +169% 31 Mar 2020
Q4 2019 30% +24% +358% 31 Dec 2019
Q3 2019 24% +17% +249% 30 Sep 2019
Q2 2019 17% 30 Jun 2019
Q1 2019 9.6% 31 Mar 2019
Q4 2018 6.6% 31 Dec 2018
Q3 2018 6.8% 30 Sep 2018
* An asterisk sign (*) next to the value indicates that the value is likely invalid.